We are partners to the enablers of biotech breakthroughs
Sales and Business Development for
Tools, Tech & Service Providers
We Are Your Contract Commercial Team
We are a specialized outsourced sales and business development organization dedicated to accelerating commercial success for companies in the cell and gene therapy market.
Our team combines deep industry expertise with proven sales strategies to bridge the gap between groundbreaking science and market adoption and sales.
1
Deep Market Knowledge & Insights
12 ONGOING RESEARCH PROJECTS
Our deep understanding of market dynamics enables precise audience targeting, strategic partnerships, and effective content marketing to drive commercial success.
2
Commercialization Strategy & Execution
5 ONGOING RESEARCH PROJECTS
We leverage 15+ years of CGT-specific expertise, proprietary data, and a refined sales formula to accelerate the commercialization of biotech innovations.
3
Proven Sales Process & Industry Relationships
8 ONGOING RESEARCH PROJECTS
Our structured lead generation and sales process ensures strong engagement with key decision-makers, leading to successful partnerships, sales, and investments.
4
Metrics & Continuous Improvement
8 ONGOING RESEARCH PROJECTS
Our data-driven approach, clear brand identity, and consistent messaging optimize market education and maximize commercial impact in the biotech sector
Our Founder
Susan Nichols is the CEO of Propel Biosciences and a 30-year veteran of the biotechnology industry, with a career spanning diagnostics, cell and gene therapy, and life science tools and services.
Her journey into biotech was born from personal experience — a brother with a rare disease who spent years misdiagnosed. That early exposure sparked a lifelong belief in the power of science to bring clarity and change lives.
Susan began her career in diagnostics, leading regional sales, national training, marketing, and new product launches in mature, highly competitive markets. There, she mastered the commercialization fundamentals that turn innovation into adoption.
Today, she brings that strategic rigor to the emerging biotech landscape — helping CGT and high-science companies navigate the commercialization gap with clarity, discipline, and urgency.
Susan has served as CEO of a genetically modified cell therapy company and CBO of a global viral vector CDMO. She’s held executive roles at industry leaders including Invetech/Danaher, Thermo Fisher/ASI, Hitachi Chemical, and Roche Diagnostics, and has driven commercial growth across CDMO, engineering services, drug development, and manufacturing technologies.
She is a respected leader in the regenerative medicine space, sits on the Board of Directors for the Alliance for Regenerative Medicine, and is a passionate advocate for patient-driven innovation, diversity in biotech leadership, and the success of early-stage life science ventures.
From funding to partnerships, from startup to scale, Susan brings the depth, network, and executional excellence to drive biotech innovation forward — all the way to market success.
